Evidence map›Paper›PMID 29274321›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2018

Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages.

Jaeyoon Chung, Xulong Wang, Toru Maruyama, Yiyi Ma, Xiaoling Zhang, Jesse Mez, Richard Sherva, Haruko Takeyama, Alzheimer's Disease Neuroimaging Initiative, Kathryn L Lunetta and 2 more

Open access · greenAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 4 pooled it
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Jaeyoon ChungBioinformatics Graduate Program, Boston University, Boston, MA, USA; Department of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA.
Xulong WangNeurogenetics and Integrated Genomics, Andover Innovative Medicines (AiM) Institute, Eisai Inc, Andover, MA, USA.
Toru MaruyamaDepartment of Life Science & Medical Bioscience, Waseda University, Tokyo, Japan; Computational Bio-Big Data Open Innovation Lab, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.
Yiyi MaDepartment of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA.
Xiaoling ZhangDepartment of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA.
Jesse MezDepartment of Neurology, Boston University, Boston, MA, USA.
Richard ShervaDepartment of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA.
Haruko TakeyamaDepartment of Life Science & Medical Bioscience, Waseda University, Tokyo, Japan; Computational Bio-Big Data Open Innovation Lab, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan; Research Organization for Nano & Life Innovation, Waseda University, Tokyo, Japan.
Alzheimer's Disease Neuroimaging Initiative
Kathryn L LunettaDepartment of Biostatistics, Boston University, Boston, MA, USA.
Lindsay A FarrerBioinformatics Graduate Program, Boston University, Boston, MA, USA; Department of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA; Department of Neurology, Boston University, Boston, MA, USA; Department of Biostatistics, Boston University, Boston, MA, USA; Department of Ophthalmology, Boston University, Boston, MA, USA; Department of Epidemiology, Boston University, Boston, MA, USA.
Gyungah R JunDepartment of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA; Neurogenetics and Integrated Genomics, Andover Innovative Medicines (AiM) Institute, Eisai Inc, Andover, MA, USA. Electronic address: gyungah_jun@eisai.com.
Boston University · USWaseda University · JPAndover Eye Associates · US

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4M
Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1M
Alzheimer Disease Genetic Architecture in African AmericansR01AG048927 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Lindsay A. Farrer · 2015 to 2026
$8.4M
Genomic and Biological Studies of APOE ε2 in Alzheimer DiseaseRF1AG057519 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARRER, LINDSAY A., JUN, GYUNGAH · 2017 to 2017
$2.4M
Genetic and Neuropsychological Heterogeneity in Alzheimer's DiseaseK23AG046377 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MEZ, JESSE BENJAMIN · 2014 to 2018
$639k
NIA NIH HHS K23 AG046377NIA NIH HHS P30 AG013846NIA NIH HHS R01 AG048927NIA NIH HHS RF1 AG057519NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG032984NIA NIH HHS U19 AG024904NIA NIH HHS U24 AG021886
6 · The paper itself

Abstract

introductionGenetic associations for endophenotypes of Alzheimer's disease (AD) in cognitive stages preceding AD have not been thoroughly evaluated.

methodsWe conducted genome-wide association studies for AD-related endophenotypes including hippocampal volume, logical memory scores, and cerebrospinal fluid Aβ

resultsIn CN subjects, study-wide significant (P < 8.3 × 10 DISCUSSION: Our findings for AD-related brain changes before AD provide insight about early AD-related biological processes.

Indexed as

EndophenotypesGenome-Wide Association StudyPolymorphism, Single NucleotideAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionEarly DiagnosisFemaleHumansMagnetic Resonance ImagingMaleNerve Tissue ProteinsPhosphorylationtau ProteinsAmyloid beta-PeptidesBiomarkersNerve Tissue Proteinstau ProteinsADNIAlzheimer's diseaseBiomarkerCerebrospinal fluidCoexpression networkEndophenotypesGenome-wide associationLogical memoryMRITau

Identifiers

PMID29274321
PMCPMC5938137
OpenAlexW2775900076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.